Is gabapentin good for back pain
Pro Research Analysisby 
Searched over 200M research papers
Gabapentin for Back Pain: An Analysis of Efficacy and Safety
Introduction to Gabapentin and Back Pain
Gabapentin, an anticonvulsant medication, is frequently prescribed off-label for various types of pain, including chronic low back pain (CLBP). Despite its widespread use, the effectiveness and safety of gabapentin for treating back pain remain subjects of debate.
Efficacy of Gabapentin in Chronic Low Back Pain
Randomized Controlled Trials and Meta-Analyses
Several studies have investigated the efficacy of gabapentin in managing CLBP. A randomized controlled trial comparing gabapentin to a placebo over 12 weeks found no significant difference in pain reduction between the two groups, with both experiencing a 30% reduction in pain intensity1. Similarly, a systematic review and meta-analysis concluded that gabapentin showed minimal improvement in pain relief compared to placebo, with a mean difference of 0.22 units, which is not clinically significant2.
Comparative Studies with Other Analgesics
When compared to other analgesics, gabapentin did not demonstrate superior efficacy. For instance, pregabalin, another gabapentinoid, was found to be more effective than gabapentin in reducing pain associated with failed back surgery syndrome (FBSS)6. Additionally, gabapentin was less effective than other analgesics like amitriptyline and tramadol/acetaminophen combinations in treating CLBP without radiculopathy10.
Safety and Adverse Effects
Common Adverse Effects
Gabapentin is associated with several adverse effects. A systematic review highlighted that patients on gabapentin reported higher incidences of dizziness, fatigue, cognitive difficulties, and visual disturbances compared to those on placebo2. The number needed to harm for these side effects ranged from 6 to 8, indicating a relatively high risk of adverse events.
Long-Term Safety Concerns
The long-term safety of gabapentin is also a concern. The drug has been linked to misuse and addiction, leading to its reclassification as a controlled substance in some regions4. This reclassification underscores the need for caution in prescribing gabapentin for chronic pain conditions.
Pharmacodynamic Insights
A study using single-photon emission computed tomography (SPECT) provided insights into the pharmacodynamics of gabapentin in CLBP patients. The study found that gabapentin increased regional cerebral blood flow (rCBF) in the anterior cingulate gyrus and decreased rCBF in the periaqueductal gray matter, suggesting a central mechanism of action. However, non-responders showed different brain activity patterns, indicating variability in individual responses to the drug3.
Conclusion
The current evidence suggests that gabapentin is not particularly effective for managing chronic low back pain and is associated with significant adverse effects. While it may offer some pain relief for specific conditions like neuropathic pain, its use for nonspecific CLBP should be approached with caution. More high-quality, large-scale trials are needed to better understand its efficacy and safety profile in this context.
Sources and full results
Most relevant research papers on this topic
A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component
Gabapentin appears to be ineffective for analgesia in chronic low back pain, with or without a radiating component.
RCT
Rigorous JournalBenefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials
Gabapentinoids show minimal improvement in chronic low back pain and are associated with increased adverse events, but their use is increasingly recommended due to their potential benefits in neuropathic pain conditions.
Meta-AnalysisRigorous Journal
Highly CitedPharmacodynamic effect of gabapentin on central nervous system in patients with chronic low back pain: a [99mTc]Tc-ECD SPECT study
Gabapentin improves chronic low back pain by increasing pain threshold and decreasing regional cerebral blood flow in the periaqueductal gray substance.
Observational StudyGabapentinoids should not be used for chronic low back pain, meta-analysis concludes
Existing evidence does not support their use for chronic low back pain, and their use off-label may lead to increased misuse and addiction.
Meta-Analysis
Very Rigorous JournalPregabalin and gabapentin for pain
Pregabalin and gabapentin are effective for treating neuropathic pain and are often used off-label for other pain disorders like low back pain, sciatica, and migraine.
Case ReportRigorous JournalHighly CitedPregabalin versus Gabapentin Efficacy in the Management of Neuropathic Pain Associated with Failed Back Surgery Syndrome
Pregabalin is significantly more effective than Gabapentin in relieving neuropathic pain associated with failed back surgery syndrome, regardless of patients' gender.
RCTThe Efficacy of Preoperative Gabapentin in Spinal Surgery: A Meta-Analysis of Randomized Controlled Trials.
Preoperative gabapentin effectively reduces postoperative opioid consumption, visual analog scale scores, and some side effects after spinal surgery.
Meta-AnalysisMulti-day low dose ketamine infusion as adjuvant to oral gabapentin in spinal cord injury related chronic pain: a prospective, randomized, double blind trial.
Multi-day low dose ketamine infusion as an adjuvant to oral gabapentin is safe and effective in reducing pain in post-spinal cord injury patients, but the effect compared to placebo ceased 2 weeks after infusion termination.
RCTHighly CitedUsing gabapentin to treat failed back surgery syndrome caused by epidural fibrosis: A report of 2 cases.
Gabapentin monotherapy effectively improves functional status and reduces pain in patients with failed back surgery syndrome caused by epidural fibrosis.
Case ReportPregabalin and gabapentin for chronic low back pain without radiculopathy: a systematic review
Pregabalin and gabapentin show mixed results in treating chronic low back pain without radiculopathy or neuropathy, with gabapentin showing potential as a viable option.
Systematic Review